Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMED M MILHEM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558429100
CMS profile
806076
Location
IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$53.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.18 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $53.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMED M MILHEM

NPI 1558429100 · CMS profile ID 806076

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $53.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $53.1804/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242511626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,538.13 7
PY2021 $18.12 2
PY2022 $21.70 2
PY2025 $53.18 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,472.81 4
PY2025 Principal investigator $581,246.58 77
PY2024 Principal investigator $999,952.01 109
PY2023 Recipient $1,270.00 2
PY2023 Principal investigator $827,610.63 137
PY2022 Principal investigator $1,233,503.31 110
PY2021 Principal investigator $751,345.38 31
PY2020 Principal investigator $896,218.13 99
PY2019 Recipient $476.00 1
PY2019 Principal investigator $1,105,673.41 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $43,197.49 12/31/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1136410738
Principal investigator 1 Merck Sharp & Dohme LLC $3,143.78 12/31/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1136410742
Principal investigator 1 Merck Sharp & Dohme LLC $8,049.28 12/31/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1136414176
Principal investigator 1 Merck Sharp & Dohme LLC $137,051.33 12/31/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with Pembrolizumab Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma KEYVIBE-010 No dispute reported 06/30/2026 1136428492
Principal investigator 1 Merck Sharp & Dohme LLC $358,094.10 12/31/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 No dispute reported 06/30/2026 1136437589
Principal investigator 3 Merck Sharp & Dohme LLC $30,192.20 12/20/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1136411266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38,220.18 12/20/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $274.05 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,877.20 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,226.48 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,039.30 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,159.00 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,890.00 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $612.36 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,047.50 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,505.70 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,557.36 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.59 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $675.00 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $346.50 12/02/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409555
Principal investigator 1 Immunocore Limited $326.71 09/19/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1103129703
Principal investigator 1 Genentech, Inc. $2,000.00 09/10/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376352
Principal investigator 1 Genentech, Inc. $725.00 09/10/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376356
Principal investigator 1 Genentech, Inc. $26,736.00 09/10/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376358
Principal investigator 1 Genentech, Inc. $2,250.00 09/10/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.28 09/09/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.28 09/09/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409497
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 09/06/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520870
Principal investigator 1 ADC Therapeutics America, Inc. $725.00 09/06/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520872
Principal investigator 1 ADC Therapeutics America, Inc. $500.00 09/06/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520874
Principal investigator 1 ADC Therapeutics America, Inc. $4,150.00 09/06/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520876
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,106.00 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134509
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,727.00 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134511
Principal investigator 1 Deciphera Pharmaceuticals Inc. $600.00 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134513
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,500.00 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134515
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,034.00 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.28 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $274.05 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54.81 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.28 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.28 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.28 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $505.38 09/04/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409493
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,843.58 08/31/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Study of DF6002 Alone and in Combination With Nivolumab No dispute reported 06/30/2026 1123473669
Principal investigator 1 Merck Sharp & Dohme LLC $16,248.18 08/21/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1136410747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57,141.95 08/05/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409479
Principal investigator 1 PFIZER INC. $1,200.00 07/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1130948630
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $2,631.91 06/25/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131056195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 06/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 06/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 06/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,721.16 06/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $274.05 06/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.81 06/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409469
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $14,254.50 06/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131046920
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $1,460.00 06/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131046926
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $3,489.88 06/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131048047
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $725.00 06/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131048086
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $1,100.00 06/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131048093
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $2,250.00 06/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131055713
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $2,500.00 06/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131056201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,677.56 05/17/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409445
Principal investigator 1 PFIZER INC. $600.00 05/08/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1130947516
Principal investigator 1 Genentech, Inc. $689.00 05/07/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376346
Principal investigator 1 Genentech, Inc. $10,348.00 05/07/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376350
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 04/29/2024 Non-covered Recipient Entity
University Of Iowa
MRD Monotherapy, combination of VSV-GP w/ antiPD1 No dispute reported 06/30/2026 1101072227
Principal investigator 1 Genentech, Inc. $4,230.00 04/25/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376348
Principal investigator 1 PFIZER INC. $54,941.00 04/24/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1130947522
Principal investigator 1 PFIZER INC. $1,200.00 04/24/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1130948636
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,767.00 04/15/2024 Non-covered Recipient Entity
AHS Hospital Corp Atlantic Health System
MRD Monotherapy, combination of VSV-GP w/ antiPD1 No dispute reported 06/30/2026 1101072229
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,725.00 04/03/2024 Non-covered Recipient Entity
State University Of Iowa Ste 168c
MRD Monotherapy, combination of VSV-GP w/ antiPD1 No dispute reported 06/30/2026 1101072231
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $1,580.80 03/15/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131055016
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $1,650.00 03/15/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131055027
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $5,076.50 03/15/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131055550
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $809.28 03/15/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131055920
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $2,056.60 03/15/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131056378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $418.95 03/06/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $329.17 03/06/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,575.00 03/06/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,575.00 03/06/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082409433
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $1,650.00 02/26/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1131056382
Principal investigator 1 Genentech, Inc. $4,577.00 02/06/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1133376344
Principal investigator 1 GlaxoSmithKline, LLC. $3,465.00 01/29/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
LONG TERM FOLLOW-UP OF PARTICIPANTS EXPOSED TO GSK3377794 (NY-ESO-1C25 No dispute reported 06/30/2026 1127521123
Principal investigator 1 Immunocore Limited $653.42 01/29/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1103129643
Principal investigator 1 GlaxoSmithKline, LLC. $10,000.00 01/26/2024 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1127521125
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 01/26/2024 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1127521127
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 01/26/2024 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1127521129
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 01/26/2024 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1127521131
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 01/26/2024 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1127521133
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,000.00 01/19/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134503
Principal investigator 1 Deciphera Pharmaceuticals Inc. $10,000.00 01/19/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134505
Principal investigator 1 Deciphera Pharmaceuticals Inc. $750.00 01/19/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1146134507
Principal investigator 1 ADC Therapeutics America, Inc. $550.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520816
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520818
Principal investigator 1 ADC Therapeutics America, Inc. $500.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520822
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520840
Principal investigator 1 ADC Therapeutics America, Inc. $550.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520848
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520850
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520852
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520854
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520856
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520858
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520860
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520862
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520864
Principal investigator 1 ADC Therapeutics America, Inc. $500.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520866
Principal investigator 1 ADC Therapeutics America, Inc. $750.00 01/05/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1126520868